[THE EFFECT OF CYTOFLAVIN ON PARAMETERS OF THE LEFT VENTRICULAR SYSTOLIC FUNCTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION.]

Publisher: Izd-vo Meditsina Country of Publication: Russia (Federation) NLM ID: 9215981 Publication Model: Print Cited Medium: Print ISSN: 0869-2092 (Print) Linking ISSN: 08692092 NLM ISO Abbreviation: Eksp Klin Farmakol Subsets: MEDLINE

Original Publication: Moskva : Izd-vo Meditsina

Cardiotonic Agents/*therapeutic use ; Flavin Mononucleotide/*therapeutic use ; Heart Ventricles/*drug effects ; Inosine Diphosphate/*therapeutic use ; Myocardial Infarction/*drug therapy ; Niacinamide/*therapeutic use ; Stroke Volume/*drug effects ; Succinates/*therapeutic use ; Ventricular Function, Left/*drug effects; Adult ; Aged ; Biomarkers/blood ; Case-Control Studies ; Coronary Vessels/drug effects ; Coronary Vessels/physiopathology ; Coronary Vessels/surgery ; Creatine Kinase/blood ; Creatine Kinase/genetics ; Drug Administration Schedule ; Drug Combinations ; Female ; Gene Expression ; Humans ; Male ; Middle Aged ; Myocardial Infarction/physiopathology ; Myocardial Infarction/surgery ; Stents ; Systole/drug effects ; Treatment Outcome ; Troponin I/blood ; Troponin I/genetics

The effect of cytoflavin on parameters of the left ventricular systolic function (LVSF) during acute myocardial infarction was studied in a group of 46 patients which received this drug (in addition to standard therapy) intravenously as 20 mL of Polysan solution (St. Petersburg, Russia) diluted in 250 mL of 5% glucose solution once a day 30 min before coronary artery recanalization. The control group of 60 patients received only standard therapy. The drug effectiveness was evaluated in terms of LVSF parameters including the ejection fraction, end-diastolic volume, and end-systolic volume. The introduction of cytoflavin to pati- ents led to (i) increase in the ejection fraction of left ventricle by 7.9% as compared to patients of the control group and (ii) decrease in the end-diastolic and end-systolic volume of the left ventricle on 7th day of hospitalization by 10.6% and 17.9%, respectively (p < 0.05). The addition of cytoflavin to standard the- rapy significantly reduced the level of troponin I on the 7th day in patients with acute myocardial infarction down to 81% relative to the control and the activity of creatine kinase by 35% (p < 0.05). The inclusion of cytoflavin in the treatment of patients with acute myocardial infarction should be considered as pathoge- netically proved, clinically justified, and promising therapy.

0 (Biomarkers)
0 (Cardiotonic Agents)
0 (Drug Combinations)
0 (Succinates)
0 (Troponin I)
0 (cytoflavin)
25X51I8RD4 (Niacinamide)
7N464URE7E (Flavin Mononucleotide)
86-04-4 (Inosine Diphosphate)
EC 2.7.3.2 (Creatine Kinase)

Date Created: 20180607 Date Completed: 20180626 Latest Revision: 20180626

20221213

29873997